Zidovudine potentiates local and systemic inflammatory responses in the rat

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 14, Issue 5, 1997, Pages 399-407

  Raymond, Philippe ^a   Biais Jr , Charles ^a   Décarie, Anick ^a   Morais, Réjean ^a   Adam, Albert ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Albumin; Carrageenan; Inflammation; T kininogen; Zidovudine; 1 Inhibitor 3

Indexed keywords

ACUTE PHASE PROTEIN; ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA1 PROTEINASE INHIBITOR III; ASPARTATE AMINOTRANSFERASE; CARRAGEENAN; CHLORAMPHENICOL; CYTOCHROME C OXIDASE; KININOGEN; MESSENGER RNA; PLASMA PROTEIN; ZIDOVUDINE;

ACUTE PHASE RESPONSE; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOT HYBRIDIZATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; INFLAMMATION; LIVER; LONG TERM CARE; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PAW EDEMA; PRIORITY JOURNAL; RAT; SERUM;

ANIMALIA;

EID: 0030946204     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199704150-00002     Document Type: Article

References (79)

1. Kozin F, Cochrane CG. The contact activation system of plasma: biochemistry and pathophysiology. In: Gallin JI, Goldstein IM, Snyderman R, eds. Inflammation: basic principles and clinical correlates. New York: Raven Press, 1992:103-21.
2. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994;15:74-80.
3. Moreau T, Esnard F, Gutman N, Degand P, Gauthier F. Cysteine-proteinase inhibiting function of T-kininogen and of its proteolytic fragments. Eur J Biochem 1988;173:185-90.
4. 1-inhibitor-3. J Biol Chem 1989;264:11428-35.
5. Mitsuya H, Weinhold KJ, Furman PA, et al. 3′-Azido-3′-deoxythymidine (BW A509U): An antiviral agents that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 1985;82:7096-100.
6. Chen CH, Vazquez-Padua M, Cheng YC. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol Pharmacol 1991;39:625-8.
7. Lewis W, Papoian T, Gonzalez B, Louie H, Kelly DP, Payne M, Grody WW. Mitochondrial ultrastructural and molecular changes induced by zidovudine in rat hearts. Lab Invest 1991;65:228-36.
8. Arnaudo E, Dalakas M, Shanske S, Moraes CT, DiMauro S, Schon EA. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 1991;337:508-10.
9. Mhiri C, Baudrimont M, Bonne G, et al. Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction. Ann Neurol 1991;29:606-14.
10. Ioannou MI, Tsawdaroglou N, Sekeris CE. Presence of glucocorticoid responsive element in the mitochondrial genome. Anticancer Res 1988;8:1405-10.
11. Kadowaki T, Kitagawa Y. Enhanced transcription of mitochondrial genes after growth stimulation and glucocorticoid treatment of Reuber hepatoma H-35. FEBS Lett 1988;233:51-6.
12. Van Itallie MC. Dexamethasone treatment increases mitochondrial RNA synthesis in rat hepatoma cell line. Endocrinology 1992;130:567-76.
13. Demonacos C, Tsawdaroglou NC, Djordjevic-Markovic R, et al. Import of the glucocorticoid receptor into rat liver mitochondria in vivo and in vitro. J Steroid Biochem Mol Biol 1993;46:401-13.
14. Richtsmeier WJ, Grossberg SE. Inhibitory effects of mitochondrial metabolic inhibitors on interferon action. J Interferon Res 1989;9:87-96.
15. Schulze-Osthoff K, Bakker AC, Vanhaesebroeck B, Beyaert R, Jacob WA, Fiers W. Cytotoxic activity of tumor necrosis factor is mediated by early damage of mitochondrial functions. J Biol Chem 1992;267:5317-23.
16. Schulze-Osthoff K, Beyaert R, Vandevoorde V, Haegeman G, Fiers W. Depletion of the mitochondrial electron transport abrogates the cytotoxic and gene-inductive effects of TNF. EMBO J 1993;12:3095-104.
17. 2-kininogen in liver. J Pharmacol Exp Ther 1996;278:934-40.
18. Adam A, Damas J, Renard C, Calay G, Bourdon V. Purification and characterization of plasma T-kininogen from Wistar and brown Norway rats. Biochem Cell Biol 1989;67:86-92.
19. Gauthier F, Ohlsson K. Isolation and some properties of a new enzyme-binding protein in rat plasma. Z Physiol Chem 1978;359:987-92.
20. Hall JM, Hallet C. A simple precise method for measuring rodent paw volume. J Pharm Pharmacol 1975;27:623.
21. Tijssen P. Practice and theory of enzyme immunoassays. In: Burton RH, Von Knippenberg PH, eds. Laboratory techniques in biochemistry and molecular biology. Amsterdam: Elsevier, 1985;238-407.
22. Peters T Jr, Biamonte GT, Doumas BT. Protein (total protein) in serum, urine, and cerebrospinal fluid; albumin in serum. In: Faulkner WR. Meites S. eds. Selected methods of clinical chemistry, vol 9. Washington, DC: American Association for Clinical Chemistry, 1982:161-245.
23. Peterson GL. Determination of total protein. Methods Enzvmol 1983;91:95-121.
24. Morais R. Studies on the localization of the rat mitochondrial 5'-endonuclease. Biochim Biophys Acta 1969;189:38-45.
25. Farrell RE. RNA isolation strategies. In: Jovanovich HB, ed. RNA methodologies: a laboratory guide for isolation and characterization. New York: Academic Press. 1993:46-92.
26. 1-protein (thiostatin) and kininogen in the rat. J Biol Chem 1987;262:9298-308.
27. Wallenstein S, Zucker CL, Fleis JL. Some statistical methods useful in circulation research. Circ Res 1980;47:1-9.
28. Vinegar R, Truax JF, Selph JL, Johnston PR, Venable AL, Mckenzie KK. Pathway to carrageenan-induced inflammation in the hind limb of rat. Fed Proc 1987;46:118-26.
29. Corcuera T, Alonso MJ, Picazo A, et al. Hepatic morphological alterations induced by zidovudine (ZDV) in an experimental model. Pathol Res Pract 1996;192:182-7.
30. Damas J, Remacle-Volon G. Rôle des kinines dans l'oedème tégumentaire déclenché par les carragénines chez le rat. J Pharmacol 1982;13:225-39.
31. Wei X, Charles IG, Smith A, et al. Altered immune responses in mice lacking inducible nitric oxide synthase. Nature 1995;375:409-11.
32. Thompson MB, Dunnick JK, Sutphin ME, Giles HD, Irwin RD, Prejean JD. Hematologic toxicity of AZTand ddC administered as single agents and in combination to rats and mice. Fundam Appl Toxicol 1991;17:159-76.
33. Sikka SC, Gogu SR, Agrawal KC. Effect of zidovudine (AZT) on reproductive and hematopoietic system in the male rat. Biochem Pharmacol 1991;42:1293-7.
34. Gallicchio VS, Hughes NK, Tse KF, Lucille P. Prevention of hematopoietic myeloid and megakaryocyte toxicity associated with zidovudine in vivo in mice with recombinant GM-CSF. Growth Regul 1994;4:41-7.
35. Fischl MA. New developments in dideoxynucleoside antiretroviral therapy for HIV infection. AIDS Clin Rev 1991:197-214.
36. Morris DJ. Adverse effects and drug interactions of clinical importance with antiviral drugs. Drug Saf 1994;10:281-91.
37. Mc Kallip RJ, Nagarkatti M, Nagarkatti PS. Immunotoxicity of AZT: inhibitory effect on thymocyte differentiation and peripheral T cell responsiveness to gp120 of human immunodeficiency virus. Toxicol Appl Pharmacol 1995;131:53-62.
38. 9]BK in carrageenan-induced edema. Peptides 1996;17:1009-15.
39. Oddis CV, Finkel MS. Cytokine-stimulated nitric oxide production inhibits mitochondrial activity in cardiac myocytes. Biochem Biophys Res Commun 1995;213:1002-9.
40. Brown GC. Nitric oxide regulates mitochondrial respiration and cell functions by inhibiting cytochrome oxidase. FEBS Lett 1995;369:136-9.
41. Modica-Napolitano JS. AZT causes tissue-specific inhibition of mitochondrial bioenergetic function. Biochem Biophys Res Commun 1993;194:170-7.
42. Hobbs GA, Keilbaugh SA, Rieff PM, Simpson MV. Cellular targets of 3′-azido-3′-deoxythymidine: an early (non-delayed) effect on oxidative phosphorylation. Biochem Pharmacol 1995;50:381-90.
43. Andus T, Geiger T, Hirano T, Kishimoto T, Tran-Thi TA, Decker K. Regulation of synthesis and secretion of major acute-phase proteins by recombinant human interleukin-6 (BSF-2/IL-6) in hepatocyte primary cultures. Eur J Biochem 1988;173:287-93.
44. Geiger T, Andus T, Klapproth J, Hirano T, Kishimoto T, Heinrich PC. Induction of rat acute-phase proteins by interleukin-6 in vivo. Eur J Immunol 1988;18:717-21.
45. Anderson KP, Croyle ML, Lingrel JB. Primary structure of a gene encoding rat T-kininogen. Gene 1989;81:119-28.
46. Anderson KP, Lingrel JB. Differential regulation of rat T-kininogen by tumor necrosis factor and interleukin-6. Mol Endocrinol 1990;4:543-50.
47. Gauldie J, Richards C, Harnish D, Lansdorp P, Baumann H. Interferon β2/BSF-2 shares identity with monocyte derived hepatocyte stimulating factor (HSF) and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 1987;84:7251-5.
48. Baumann H, Onorato V, Gauldie J, Jahreis GP. Distinct sets of acute phase plasma proteins are stimulated by separate human hepatocyte-stimulating factors and monokines in rat hepatoma cells. J Biol Chem 1987;262:9756-68.
49. De Jong FA, Birch HE, Schreiber G. Effects of recombinant interleukin-1 on mRNA levels in rat liver. Inflammation 1988;12:613-7.
50. Sadeghi HM, Weiss L, Kazatchkine MD, Haeffner-Cavaillon N. Antiretroviral therapy suppresses the constitutive production of interleukin-1 associated with human immunodeficiency virus infection. J Infect Dis 1995;172:547-50.
51. Wal JM, Corpet DE, Peleran JC, Bones GF. Comparative metabolism of CAP in germ-free and conventional rats. Antimicrob Agents Chemother 1983;24:89-94.
52. Cretton EM, Xie MY, Bevan RJ, Goudgaon NM, Schinazi RF, Sommadossi JP. Catabolism of 3′-azido-3′-deoxythymidine in hepatocytes and liver microsomes, with evidence of formation of 3′-amino-3′-deoxythymidine, a highly toxic catabolite for human bone marrow cells. Mol Pharmacol 1991;39:258-66.
53. Johns DR. Mitochondrial DNA and disease. N Engl J Med 1995;333:638-44.
54. Lestienne P, Bataillé N. Mitochondrial DNA alterations and genetic diseases: a review. Biomed Pharmacother 1994;199-214.
55. Parikh VS, Morgan MM, Scot R, Clements LS, Butow RA. The mitochondrial genotype can influence nuclear gene expression in yeast. Science 1987;235:576-80.
56. Liao X, Small WC, Srere PA, Butow RA. Intramitochondrial functions regulate nonmitochondrial citrate synthase (CIT 2) expression in Saccharomyces cerevisiae. Mol Cell Biol 1991; 11:38-46.
57. Wang H, Parent M, Morais R. Cloning and characterization of a cDNA encoding elongation factor 1 alpha from chicken cells devoid of mitochondrial DNA. Gene 1994;140:155-61.
58. Chrzanowska-Lightowlers ZMA, Preiss T, Lightowlers RN. Inhibition of mitochondrial protein synthesis promotes increased stability of nuclear-encoded respiratory gene transcripts. J Biol Chem 1994;269:27322-8.
59. Zybler E, Berco C, Penman S. Selective inhibition of the synthesis of mitochondria-associated RNA by ethidium bromide. J Mol Biol 1969;44:195-204.
60. Desjardins P, Frost E, Morais R. Ethidium bromide-induced loss of mitochondrial DNA from primary chicken embryo fibroblasts. Mol Cell Biol 1985;5:1163-9.
61. Morais R. Isolation of avian mitochondrial DNA-less cells. Methods Enzymol 1996;264:296-304.
62. Evans MJ, Scarpulla RC. Interaction of nuclear factors with multiple sites in the somatic cytochrome c promoter: characterization of upstream NRF-1, ATF, and intron Sp1 recognition sites. J Biol Chem 1989;264:14361-8.
63. Suzuki H, Hosokawa Y, Nishikimi M, Ozawa T. Existence of common homologous elements in the transcriptional regulatory regions of human nuclear genes and mitochondrial gene for the oxidative phosphorylation system. J Biol Chem 1991;266:2333-8.
64. Suzuki H, Suzuki S, Kumar S, Ozawa T. Human nuclear and mitochondrial Mt element-binding proteins to regulatory regions of the nuclear respiratory genes and to the mitochondrial promoter region. Biochem Biophys Res Commun 1995;213:204-10.
65. Virbisius JV, Virbisius CA, Scarpulla RC. Identity of GABP with NRF-2, a multisubunit activator of cytochrorae oxidase expression, reveals a cellular role for an ETS domain activator of viral promoters. Genes Dev 1993;7:380-92.
66. Chen SC, Barker SM, Mitchell DH, et al. Concurrent zidovudine-induced myopathy and hepatotoxicity in patients treated for human immunodeficiency virus (HIV) infection. Pathology 1992;24:109-11.
67. Freiman JP, Helfert KE, Hamrell MP, Stein DS. Hepatomegaly with severe steatosis in HIV-positive patients. AIDS 1993;7:379-85.
68. Stein TP, Nutinsky C, Condoluci D, Schluter MD, Leskiw MJ. Protein and energy substrate metabolism in AIDS patients. Metabolism 1990;8:876-81.
69. 1-Acid glycoprotein levels in AIDS patients before and after short-term treatment with zidovudine (ZDV). J Acquir Immune Defic Syndr 1993;6:531-3.
70. Keilová H, Tomásek V. Naturally occuring inhibitors of intracellular proteinases. Acta Biol Med Ger 1977;36:1873-81.
71. Lah TT, Kokalj-Kunovar M, Turk V. Cysteine proteinase inhibitors in human cancerous tissue and fluids. Biol Chem 1990;371(Suppl):199-203.
72. Björck L, Grubb A, Kjellen L. Cystatin C, a human proteinase inhibitor, blocks replication of Herpes simplex virus. J Virol 1990;64:941-43.
73. Herwald H, Collin M, Müller-Esterl W, Björck L. Streptococcal cysteine proteinase releases kinins: a novel virulence mechanism. J Exp Med 1996;184:665-73.
74. Bennasr A, Olsen A, Sjöbring U, Müller-Esterl W, Björck L. Assembly of human contact phase proteins and release of bradykinin at the surface of curli-expressing Escherichia coli. Mol Microbiol 1996;20:927-35.
75. Linnane AW, Degli Esposti M, Generowicz M, Luff AR, Nagley P. The universality of bioenergetic disease and amelioration with redox therapy. Biochim Biophys Acta 1995; 1271:191-4.
76. Wallace DC. Mitochondrial genetics: a paradigm for aging and degenerative diseases? Science 1992;256:628-32.
77. Wallace DC. Mitochondrial DNA mutations in diseases of energy metabolism. J Bioenerg Biomembr 1994;26:241-50.
78. Sierra F, Fey GH, Guigoz Y. T-kininogen expression is induced during aging. Mol Cell Biol 1989;9:5610-6.
79. Sierra F. Both T- and K-kininogens increase in the serum of old rats but by different mechanisms. Mech Ageing Dev 1995;84:127-37.